Literature DB >> 19688073

A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome.

Eun Jin Kwon1, Se Won Kim, Kwang Ki Kim, Hyung Suk Seo, Do Yeun Kim.   

Abstract

A 58-year-old female receiving gemcitabine and cisplatin chemotherapy for stage IV gallbladder cancer developed the clinicoradiologic syndrome, posterior reversible encephalopathy syndrome (PRES). Just before the 4th gemcitabine chemotherapy cycle, she was admitted to the hospital with complaints of headache, dizziness, and generalized tonic-clonic seizures. A MRI was performed on the day when the seizure developed, and the findings showed patchy cortical and subcortical T2 hyperintensity without enhancement that involved both occipital and parietal lobes. Phenytoin loading and maintenance was started for prevention of recurrent seizures, which was successful. The follow-up brain MRI obtained 10 days after the seizure attack showed completely resolved radiologic findings. After the MRI findings revealed complete resolution, phenytoin maintenance was stopped. Even with discontinuation of phenytoin, she had no seizures or other clinical manifestations.

Entities:  

Keywords:  Cisplatin; Gemcitabine; Posterior reversible encephalopathy syndrome (PRES)

Year:  2009        PMID: 19688073      PMCID: PMC2699096          DOI: 10.4143/crt.2009.41.1.53

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  13 in total

1.  Neurological symptoms associated with cyclosporin plus doxorubicin.

Authors:  W T Beck; J F Kuttesch
Journal:  Lancet       Date:  1992-08-22       Impact factor: 79.321

2.  Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

Authors:  P S Rangi; W J Partridge; E S Newlands; A D Waldman
Journal:  Neuroradiology       Date:  2005-07-05       Impact factor: 2.804

3.  Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

Authors:  Rangaswamy Govindarajan; Josna Adusumilli; Donna L Baxter; Anthony El-Khoueiry; Sami I Harik
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

Review 4.  Cytarabine and neurologic toxicity.

Authors:  W J Baker; G L Royer; R B Weiss
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

5.  Dexamethasone-induced posterior reversible encephalopathy syndrome.

Authors:  William Irvin; Gigi MacDonald; J Keith Smith; William Y Kim
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

6.  Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

Authors:  Y Ito; Y Arahata; Y Goto; M Hirayama; M Nagamutsu; T Yasuda; T Yanagi; G Sobue
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

7.  Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction.

Authors:  J D Port; N J Beauchamp
Journal:  Radiographics       Date:  1998 Mar-Apr       Impact factor: 5.333

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.

Authors:  Anita Rajasekhar; Thomas J George
Journal:  Oncologist       Date:  2007-11

10.  Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.

Authors:  S G Cho; H Moon; J H Lee; S Y Lee; C C Kim; K S Lee
Journal:  J Korean Med Sci       Date:  1999-02       Impact factor: 2.153

View more
  14 in total

1.  Diagnostic uncertainty around seizures in advanced malignancy.

Authors:  Demiana Lenzi Lewis-Hanna; Gurjeet Pamma
Journal:  BMJ Case Rep       Date:  2011-12-21

2.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

3.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors:  Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

4.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

Review 5.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

6.  Rituximab as a possible cause of posterior reversible encephalopathy syndrome.

Authors:  Ahmed Imran Siddiqi
Journal:  Australas Med J       Date:  2011-09-30

Review 7.  Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients.

Authors:  Eileen M Le; Monica E Loghin
Journal:  Curr Oncol Rep       Date:  2014-05       Impact factor: 5.075

8.  Gemcitabine monotherapy associated with posterior reversible encephalopathy syndrome.

Authors:  Luiz Carlos Porcello Marrone; Bianca Fontana Marrone; Julia de la Puerta Raya; Giovani Gadonski; Jaderson Costa da Costa
Journal:  Case Rep Oncol       Date:  2011-02-16

9.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

10.  A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.

Authors:  Hannah Cherniawsky; Neesha Merchant; Micheal Sawyer; Maria Ho
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.